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Objectives
Previous studies reported inherited BRCA1/2 deficits can cause cancer by impairing 
normal protective responses.   Opportunistic carcinogens can exploit these deficits by caus-
ing chronic inflammation, constant cell death and replacement in a mutagenic environment, 
DNA crosslinking or double strand breaks.  Some of the resulting cancers may be prevented 
if opportunistic carcinogens are identified.
Methods
The literature was systematically searched for carcinogens capable of exploiting defi-
cits in BRCA1/2 pathways.   Search criteria were common exposure, available information, 
required BRCA1/2 pathway repairs, increased risks for any cancer, and effects on stem cells.
Results
Formaldehyde and acetaldehyde are closely related carcinogens and common pollut-
ants that seem everywhere.  Alcohol metabolism also produces acetaldehyde.  High levels 
of either carcinogen overwhelm normal detoxification systems, cause inflammation, inhibit 
DNA repair and produce DNA cross links as critical carcinogenic lesions.  Searching model 
system studies revealed both carcinogens activate stem cells, BRCA1/2 pathways and con-
nected BRCA1/2 pathways to myeloid leukemia.  For example, the BRCA1-BARD1 complex 
is required for proper nucleophosmin functions.  Nucleophosmin prevents a major subset 
of acute myeloid leukemia (AML).  Next, these concepts were independently tested against 
risks for myeloid leukemia.  Epidemiologic results showed that BRCA2 gene defects inherited 
on both chromosomes increased risks so dramatically that AML occurs in most children.  
Using data from 14 studies, known/potential heterozygous BRCA1/BRCA2 mutations in-
creased risks for myeloid leukemias by at least 3 fold in 7 studies and by at least 50% in 12.  
Acetaldehyde occurs in breast milk.  In model studies, excessive acetaldehyde/alco-
hol exposure affects estrogen metabolism and stimulates alternate alcohol detoxification 
pathways.  These pathways can also cause DNA cross linking by releasing oxygen species and 
activating procarcinogens.  Acetaldehyde in rats’ drinking water increased incidence of leu-
kemias, lymphomas, pancreatic tumors and fibroadenomas.  Six human epidemiologic studies 
support an association between alcohol related genotype or alcohol consumption and early 
onset breast cancers, including those in BRCA1/2 mutation carriers. 
Conclusions  
Although it is difficult to prove direct causation, BRCA1/2 mutation carriers may 
reduce cancer risks by avoiding excessive formaldehyde and acetaldehyde.  Broader genetic 
testing and pharmacologic/nutritional detoxification are possible.  
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Background
Previous explanations for the tissue 
specificity of hereditary breast cancer.   In 
order to prevent or delay hereditary cancers it 
is essential to understand why some hereditary 
cancers seem to target specific organs.  BRCA1 
and BRCA2 mutations were thought to have an 
exquisite specificity in causing breast and ovar-
ian cancer.   Several explanations for this specific 
targeting have been published.
One published explanation is because 
the breast does not have back up systems or 
redundancy to compensate for the absence 
of BRCA1/2 functions.  Back ups for some 
BRCA1/2 function are general methods of DNA 
repair such as non-homologous end joining, or 
translesion synthesis.  When forced into service 
inappropriately because of abnormal BRCA1/2 
pathways, repairs become less accurate and risks 
for some cancers increase.  [e.g.  Venkitaraman 
(2003), Lagerqvist (2008), Friedenson (2007)].  
Cancers that depend on gene translocations may 
occur because double strand breaks are repaired 
by combining inappropriate pieces of broken 
chromosomes.   One cancer strongly associated 
with a reciprocal translocation is mantle cell lym-
phoma.  The incidence of mantle cell lymphoma 
increased 70 fold when the BRCA1/2 pathway 
molecule ATM was inactivated [Friedenson, 
2007].  At least in some cases, losses of whole 
chromosomes or fragments damage such fun-
damental and essential systems that alternative 
mechanisms are unable to compensate without 
allowing dangerous mutations [Lagerqvist et al.  
(2008)].
Another proposal is that cancer cells that 
lose both copies of BRCA1 are only able to sur-
vive in breast and ovary but die everywhere else.  
However there are homozygous defects if not in 
BRCA1, then in BRCA2,  ATM and Fanconi pro-
teins.  In these conditions every organ survives.
A different explanation depends on the 
high proliferation rates in the breast and ovary.  
Cell proliferation in the absence of BRCA1 or 
BRCA2 may lead to a higher mutation rate.  
However breast cancer and leukemias provided 
foundations for the cancer stem cell hypotheses.  
This hypothesis states that cancers originate 
from abnormal stem cells.  These retain stem cell 
ability to self renew and to differentiate asym-
metrically.  They may be rare and ordinarily do 
not proliferate.  
Another possibility is that tissue specific 
cofactors, transcription factors, hormones and 
the context of different tissues determine the 
tissue specificity of hereditary cancers.  However 
BRCA1/2 mutation carriers have increased rela-
tive risks for cancers in a wide variety of tissues 
and increased risks for cancers in general [Frie-
denson, (2005)].  
 Preventing hereditary cancers 
caused by opportunistic carcinogens. Previ-
ous work [Friedenson (2010 a, b, 2011)] sug-
gested that hereditary cancers have defects in 
processing some carcinogens from the environ-
ment because hereditary defects aggravate the 
effects of some carcinogens.  For example there 
is an increased incidence of cancers related to 
constant cell death and replacement in a muta-
genic environment such as chronic organ specific 
infections that cause DNA damage requiring 
BRCA1/2 repairs.   
 The first defenses against these carcino-
gen induced cancers are encoded by genes for 
immune responses, and for processing, detoxi-
fying and metabolizing carcinogens.  BRCA1/2 
mediated pathways then serve as further de-
fenses to repair certain types of DNA damage 
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but inherited mutations can cripple these repairs 
and other BRCA1/2 protective functions.   Op-
portunistic carcinogens that escape detoxifica-
tion pathways can take advantage of inherited 
deficiencies in BRCA1/2 pathways.  Identifying 
and minimizing exposure to opportunistic car-
cinogens is the first step in preventing or delaying 
some cancers in mutation carriers.
Methods
Identifying opportunistic carcino-
gens based on model studies.   The literature 
was systematically searched for all available years 
to identify model studies of common carcino-
gens that produce DNA cross links or DNA 
protein cross links.  Search criteria were com-
mon, unavoidable exposure, available information, 
required BRCA1/2 pathway repairs, increased 
risks for any cancer, and effects on stem cells.  
Formaldehyde and acetaldehyde were identified 
as two common pollutants and opportunistic 
carcinogens.  Both carcinogens form DNA le-
sions requiring repairs mediated by BRCA1/2 
pathways.  
Searches were then conducted for can-
cers caused by exposure to formaldehyde and 
acetaldehyde. Cancers caused by both carcino-
gens were listed.  
Cancer risks associated with op-
portunistic carcinogens tested against 
cancer risks in carriers of mutations in 
BRCA1/2 pathways.   Risks for cancers associ-
ated with exposure to opportunistic carcinogens 
were then compared to risks associated with 
mutations in BRCA1/2 pathways.  As previously 
described [Friedenson (2005, 2007, 2010a,b)], the 
literature was systematically searched for relative 
risk data on cancers in carriers or likely carriers 
of mutations in genes encoding pathways that de-
pend on BRCA1/2 genes.  Included data was used 
directly without further statistical calculation or 
combination.  Included data was not corrected 
for low percentages of mutation carriers in the 
population, for survival, or for subjects lost to fol-
low-up.  Relationships between alcohol consump-
tion and cancer risks can only can be studied in 
populations with substantial alcohol consumption 
[Seitz and Becker (2007)].   Studies could not be 
used if they contained very high percentages of 
non-drinkers or light drinkers (>=70% to 98%) 
among potential BRCA1/2 mutation carriers.  
Substantial differences in numbers of ovariecto-
mies or women on hormone replacement thera-
py in drinkers vs controls also excluded data.
Studies of second primary cancers after 
breast cancer provided the most extensive and 
complete sources of data for BRCA1/2 hetero-
aygotes.  Given the high risk of BRCA1/2 muta-
tion carriers and their involvement with medical 
oncology personnel, cancer survivors among 
patients with BRCA1/2 pathway mutations are 
often monitored for the development of a sec-
ond primary cancer.  This is done more often 
than observing genetically typed healthy individu-
als for the development of a first cancer.   
Results
Formaldehyde and acetaldehyde were 
identified as likely opportunistic carcinogens.  
Exposure is common, virtually unavoidable; expo-
sure increases risks for multiple cancers;  much 
information is available; there are clear connec-
tions with BRCA1/2 pathways in model systems, 
and both carcinogens have effects on stem cells 
[Zhang et al. (2010), Agency for toxic substances 
and disease registry (2010), Baan et al. (2009), US 
Dept Health and Human Services (1999), Nation-
al Toxicology program (2011)].   
Common and widespread exposure.  
Formaldehyde and acetaldehyde are closely relat-
ed carcinogens.   Widespread human exposures 
to formaldehyde and acetaldehyde occur during 
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Figure 1  - Carcinogenesis at high levels of formaldehyde 
competes with formaldehyde detoxification mechanisms.  
Detoxification of low levels of formaldehyde occurs primar-
ily by a pathway (thicker arrows) involving formaldehyde 
dehydrogenase (ADH1C*1 or ADH1C*2), an aldehyde dehy-
drogenase.  The pathway converts formaldehyde to formate 
which is then eliminated in the urine, broken down to CO2 
and water or enters the single carbon pool.  Alternate, less 
used pathways are indicated by thinner arrows.  Formate can 
also generate CO2- radicals and can be metabolized to CO2 
via catalase or oxidation of N-formyl tetrahydrofolate.  De-
toxification of formaldehyde does not involve BRCA1/2 but 
BRCA1/2 pathways inhibit carcinogenesis.  
production and use of many 
maufactured products.  Both 
carcinogens are also present 
in tobacco smoke, pollution 
and foods.  Formaldehyde has 
been illegally used as a food 
preservative; acetaldehyde 
forms during alcohol metabo-
lism and high levels pre-exist 
in some alcoholic beverages 
and in some foods.   Billions 
of pounds of these carcino-
gens are produced each year 
[Agency for toxic substances 
and disease registry (2010), 
Baan et al. (2009), Hauptmann 
et al. (2009),  National Toxicol-
ogy Program (2010)].   
Model studies:  Formal-
dehyde and acetaldehyde 
are opportunistic carcinogens 
causing DNA damage that 
requires repairs by BRCA1/2 
pathways.  
Formaldehyde and acetal-
dehyde chemically cross-link DNA 
strands and form DNA protein 
cross links (Fig. 1, Fig. 2).  These 
lesions are probably critical for 
carcinogenesis [Zhang et al (2010)] 
and have been demonstrated by a 
large number of studies in vitro, in 
exposed animals and in circulating 
white cells [Zhang et al. (2010), 
Ishizaka et al (2007), Shaham et al. (1996)]. 
DNA-protein cross-links exhibit a dose-
response relationship to formaldehyde in 
the respiratory tract of laboratory ani-
mals at exposure concentrations relevant 
to human exposures.  
The pathways required to repair 
DNA damage from formaldehyde and 
acetaldehye are qualitatively similar to pathways 
required to repair damage from mitomycin C.  
Mitomycin C is a known DNA crosslinking agent 
that has become a functional test for activity of 
pathways involving Fanconi proteins and including 
BRCA1/2 proteins [Marietta et al. (2009)].
Homologous recombination requiring 
BRCA1/2 and Fanconi proteins is essential to 
correct DNA protein cross links [Yamazoe et al.  
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Figure 2a. Normal detoxification of alcohol requires two 
enzymes, alcohol dehydrogenase (ADH) and then alde-
hyde dehydrogenase (ALDH).  Alcohol dehydrogease pro-
duces acetaldehyde, a mutagen and carcinogen.  Variations 
in genes encoding both enzymes influence the susceptibil-
ity to alcohol related carcinogenesis.  Fig 2b.   One mecha-
nism or carcinogenesis.    Acetaldehyde that is ingested or 
escapes alcohol detoxification pathways can form cro-
tonaldehyde, a reaction catalyzed by amine groups from 
proteins or naturally occurring amines.   Crotonaldehyde is 
genotoxic, mutagenic and carcinogenic and can be derived 
from beer, wine and liquor.  Reactions with deoxyguano-
sine in DNA produce DNA interstrand cross links and DNA 
protein cross links [Theravathu et al (2005)].  Some of 
these lesions require repairs by BRCA1/2 pathways.  Inher-
ited mutations for proteins within BRCA1/2 pathways dis-
able cross link repairs and can lead to cancer in exposed 
organs.  Excessive alcohol/acetaldehyde can also generate 
reactive oxygen species and affect estrogen, adding to 
cancer risks.
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(2004), Nojima et al. (2005), D’andrea 
and Grompe (2003), Venkitaraman 
(2003), Nakano et al (2009)].  Form-
aldehyde forms protein DNA cross 
links requiring BRCA1/2 pathway 
mediated repairs [Nakano et al (2009, 
2003)].  In mice exposed to 6 ppm 
formaldehyde for 1 week,  the Brca 
pathway is among the top 10 most 
significantly enriched pathways [An-
dersen et al. (2010)]. 
BRCA1/2 related pathways 
also participate in preventing formal-
dehyde related collateral DNA dam-
age, bone marrow toxicity and immu-
nosuppression (which can reactivate 
latent viral infections), and inflamma-
tion (which can produce cross-links 
due to oxidative damage).  These 
mutagenic environments increase the 
probability that cancer stem cells will 
arise.
Formaldehyde can exist as 
polymers which may form cross link-
ers with varying reach. Chemically 
irreversible and stable cross-linked 
products form between DNA bases 
and the amino acids cysteine, histidine 
and tryptophan.   Lysine cross-linked 
products are labile in solution, sup-
porting widely reported reversibility 
[Lu et al. (2010)].
 Acetaldehyde exposure 
places demands on BRCA1/2 
mediated pathways.  Search results 
found several lines of evidence impli-
cating acetaldehyde as the first prod-
uct of alcohol metabolism, in alcohol-
related carcinogenesis (Fig 2) [Ishizaka 
et al (2007), Lachenmeier et al (2011)]. 
Model system searches retrieved sev-
eral reports that acetaldehyde causes 
complex DNA adducts and damage 
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Figure 3  - BRCA1 and BRCA2 in DNA damage repair pathways showing prob-
able links to myeloid leukemia, other leukemias and lymphomas.  BRCA1 and 
BRCA2 are shown in pathways to correct DNA cross links and double strand 
breaks caused by formaldehyde, acetaldehyde and other agents that cause bulky 
addition products or DNA cross-links.   DNA damage is more likely if the carcino-
gen escapes metabolic detoxification pathways (Figs. 1, 2a).  Hereditary inacti-
vation of a Fanconi gene causes Fanconi anemia,  inactivation of the ATM gene 
causes ataxia-telangiectasia (A-T), and inactivation of BRCA1 or BRCA2 associ-
ates with hereditary breast/ovarian cancers.  Proteins encoded by genes related 
to these well known hereditary cancer conditions are colored red.  The dark boxes 
in the figure indicate proven links to myeloid leukemia.  The BRCA1-BARD1 com-
plex is required to activate the NPM gene which is lost in a major subset of AML.   
In AML and CML, the BCR/ABL protein interferes with the formation of nuclear 
Fanconi protein D2 repair foci.  In CML, BRCA1 becomes almost undetectable.  
The PML protein is required for Rad51 repair focus formation providing another 
link to leukemia.  Family history of leukemia increases risk for breast cancer.   
Chromosome 13q (encoding BRCA2) is deleted in a subgroup of leukemias and 
lymphomas.  Multiple other pathways participate in repairing DNA damage and 
members of the pathway shown have been implicated in coordinating repairs.   
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requiring BRCA1/2 pathway mediated repairs 
[Marietta et al 2009; Nakano et al (2003, 2009) 
Langevin et al (2011)].   Histones and naturally 
occurring polyamines facilitate the formation of 
these lesions [Theravathu et al. (2005); Sako et al 
(2003)]. (Fig. 2b). DNA adducts of  acetaldehyde 
were found in the white cells of alcohol abusers.  
Cells of the myeloid lineage were especially sus-
ceptible [Fang and Vaca (1997)].  Chinese hamster 
ovary cells show a concentration related increase 
in DNA-protein cross links [Olin et al (1996)].  
DNA from ALDH2 deficient Japanese males has 
low electrophoretic mobility, consistent with 
DNA cross link formation [Lu and Morimoto 
(2009)].   
 Many studies find that acetaldehyde 
increases the frequency of sister chromatid 
exchanges and aberrations in mammalian cells.   
Fanconi anemia cells are much more suscep-
tible than normal cells [Obe and Anderson 
(1987)].  Acetaldehyde exposure results in a 
concentration-dependent increase in Fanconi D2 
monoubiquitination, which is dependent upon the 
proper functioning of BRCA1/2 (Fig. 3).  Acetal-
dehyde also stimulates BRCA1 phosphorylation 
in a dose-dependent manner.  Meanwhile ethanol 
may suppress BRCA1 levels [Fan et al (2000)].   
Detoxification by specialized meta-
bolic pathways.  Normal metabolism produces 
both formaldehyde and acetaldehyde.   With 
some exceptions, most background dietary 
sources are generally too low to cause perma-
nent harm and are managed by reactions and 
metabolism within the digestive tract.   
Formaldehyde is primarily metabolized by 
glutathione-dependent formaldehyde dehydro-
genase (ADH3, existing in two forms renamed 
as ADH1C*1 or ADH1C*2) and aldehyde de-
hydrogenases (ALDHs) enzymes in alternative 
pathways (Fig. 1).  Formaldehyde is converted to 
formate, which is then eliminated in the urine as 
a sodium salt, broken down to CO2 and water, 
or entered into the single-carbon pool [Teng et 
al. (2001, Andersen et al, (2010)].    Other alcohol 
and aldehyde dehydrogenases can also contrib-
ute. DNA cross-links, chromosome breaks and 
chromosome abnormalities are favored if form-
aldehyde or acetaldehyde exceeds the capacity 
of detoxification pathways (Figs 1 and 2).   For 
formaldehyde, exogenous addition products form 
with DNA in a highly nonlinear fashion; a 21.7-
fold increase in exposure of rats to labeled form-
aldehyde caused a 286-fold increase in DNA-
formaldehyde addition products [Lu et al. (2011)]. 
Alcohol/Acetaldehyde detoxifica-
tion.  Alcohol metabolism utilizes ADH enzymes 
to generate acetaldehyde as a first intermediate 
and then ALDH enzymes to remove acetalde-
hyde (Fig. 2).  Variant enzymes encoded by ADH 
and ALDH genes are inherited with different 
activities and lead to differences in acetaldehyde 
accumulation and thus differences in cancer risks. 
There are seven types of ADH (Fig. 2), each en-
coded by a different gene.  Two of the seven ADH 
genes, (ADH1B and ADH1C), exist as more than 
one variant (allele). In Caucasians, the ADH1C 
gene has two known alleles: a highly active 
ADH1C*1 and less active ADH1C*2.  The AD-
H1C*1 allele encodes an ADH isoenzyme which 
produces 2.5 times more acetaldehyde than the 
corresponding allele ADH1C*2.  In studies with 
moderate to high alcohol intake,  ADH1C*1 is as-
sociated with an increased risk for cancer of the 
upper aerodigestive tract, the liver, the colon and 
the female breast [Seitz and Maurer (2007)].  
Approximately 40% of Japanese, Koreans 
or Chinese carry one copy of the acetaldehyde 
dehydrogenase 2*2 (ALDH2*2) allele. This allele 
codes for an ALDH2 enzyme with poor activ-
ity leading to high acetaldehyde concentrations 
after consuming even small amounts of alcohol.  
Chronic drinkers with this allele have significantly 
increased risks for upper alimentary tract and 
colorectal cancer.  These findings underline the 
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Table 1  Connections between BRCA1/2 containing pathways and leukemias
Leukemia Evidence for connections to BRCA1/2 pathway Reference
AML
Childen born with defects on both chromosomes af-
fecting genes encoding BRCA2 (Fanconi protein D- 
1) or both chromosomes affecting FANCN (PALB2) 
genes are especially prone to develop AML.
Alter et al (2007, 
2003). Tischkowitz et 
al  (2010)
AML
NPM is a substrate for BRCA1-BARD1.  In AML in 
China, where pollution is high, NPM is frequently lost. 
The NPM1 locus on chromosome 5 is part of a region 
that modifies breast cancer risk in BRCA1 related 
breast cancers. 
Sato JBC 2004; Wang 
et al 2010;  Nathan-
son and Weber 2002
AML, CML
BCR/ABL fusion protein inhibits the formation of 
nuclear FANCD2 foci
Valeri et al 2010
AML
ATM mutations increase the incidence of transloca-
tions at 11q23 involving the multi-lineage leukemia 
gene (MLL).  ATM prevents oncogenic translocations 
Bredemeyer et al 
2006; Sun et al, 2010
Myeloid leuke-
mias
Frequent loss of chromosome 17 [monosomy 17] 
containing BRCA1 and p53
Zhu et al 2008
Acute promyelo-
cytic leukemia 
(APL)
PML fusion protein with retinoic acid receptor causes 
loss of PML protein function.  PML is essential for 
proper localization of RAD51 in nuclear foci and effi-
cient homology directed repair.  PML also participates 
in localizing BRCA1.   
Boichuk 2011
Acute promyelo-
cytic leukemia 
(APL)
BRCA1 expression is reduced 3 to 14.3 fold in APL Casorelli et al 2006
Fanconi anemia 
associated can-
cers especially 
AML
 The model in Fig 3 shows how Fanconi proteins are 
required for activities of BRCA1 and BRCA2.
important role of acetaldehyde in ethanol-
mediated carcinogenesis [Seitz and Maurer 
(2007)].
Acetaldehyde produced after heavy 
drinking (Fig. 2a) can overwhelm natural 
metabolic systems.  Acetaldehyde is a very 
good substrate for other enzymes pres-
ent in breast cells: xanthine oxidoreductase 
(XOR) and aldehyde oxidase (AOX) [Shaw 
et al (1989), Dumitrescu and Shields (2005)].  
Methanol and formaldehyde are inhibitors of 
XOR.  Both enzymes are present and regulat-
ed in breast tissues.  Breast cancers that lack 
cytoplasmic XOR have about a 2.5 greater risk 
of metastases than those with strong XOR 
expression [Linder et al. (2005)] showing the 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
11
.6
66
8.
1 
: P
os
te
d 
5 
De
c 
20
11
-10-
importance of this enzyme.  Moreover, decreased 
XOR is associated with worse prognosis in ovar-
ian carcinoma.   
As they detoxify acetaldehyde, both XOR 
and AOX can generate superoxide, hydroxy 
radical and hydrogen peroxide.  These reactive 
oxygen species can cause complex DNA damage 
and cross links.  The generation of free radicals 
is also associated with the reaction catalyzed 
by cytochrome P-4502E1 [Jelski et al (2006)]. 
This enzyme can also convert procarcinogens to 
carcinogens.
A model for pathways containing BRCA1/2 
has several strong links to leukemias - can-
cers that can be induced by formaldehyde 
or acetaldehyde.  
 Fig. 3 is a model for BRCA1/2 function 
within a pathway for crosslink repair based on 
models of D’Andrea and Grompe (2003) and 
Venkitaraman (2003).  In Figure 3,  formaldehyde 
and acetaldehyde are inserted as sources of 
DNA damage and BRCA1/2 pathway links to my-
eloid leukemias have been added.   Table 1 sum-
marizes the search results in model systems sup-
porting these links.  Children born with defects 
on both chromosomes that affect the BRCA / 
Fanconi pathway are at high risk for AML.   These 
defects include those in BRCA2 (Fanconi protein 
D1 [Howlett et al. (2002)] and in PALB2 (Fanconi 
protein N).  Biallelic Fanconi N (PALB2) muta-
tions are associated with AML and other pediat-
ric malignancies [Tischkowitz and Xia (2010)]. 
Mutations in nucleolar phosphoprotein 
nucleophosmin/B23 (NPM) are associated with 
a major subset of AML.    The BRCA1-BARD1 
heterodimer catalyzes the ubiquitylation of NPM 
in vitro and in vivo, and BRCA1-BARD1 co-
expression in cells stabilizes NPM against degra-
dation [Sato et al (2004)].  Familial AML is linked 
to the loss of the long arm of chromosome 5 
which includes the NPM gene on chromosome 
5q33–34.  5q33-34 contains one or more genes 
that modify breast cancer risk in BRCA1 mutation 
carriers (Table 1) [Nathanson et al. (2002)].  Loss of 
genes on chromosome 4 reported byTirkkonen et 
al. (1997)] also implicates formaldehyde and alcohol 
metabolism because chromosome 4q encodes all 
the ADH genes. 
A characteristic fusion protein (BCR/ABL) 
is found in AML (and in CML).  BCR/ABL interferes 
with the formation of nuclear FANCD2 foci (Fig. 3 
and Table 1), but this interference can be reversed 
by the ectopic expression of BRCA1.  In CML, 
BRCA1 becomes virtually undetectable [Valeri et al 
(2010)].  
Fanconi protein A is lost in a subset of spo-
radic AML [Tischkowitz et al. (2004)]  Casorelli et 
al (2006) found that impaired recombination repair 
stimulated APL.    APL samples all showed major 
reductions in BRCA1 and RAD51 (Fig 3) expression. 
The promyelocytic leukemia protein (PML in Fig 3 
and Table 1) is critical for forming nuclear bodies 
with important functions in transcription, apopto-
sis, DNA repair and antiviral responses.  BRCA1 
colocalizes with these nuclear bodies [Luciani et 
al (2006)].  Loss of PML function or expression is 
associated with acute promyelocytic leukemia (APL) 
and progression of some solid tumors.   PML helps 
regulate BRCA1 [Boichuk et al, (2011)] and PML is 
critical for proper localization of the essential repair 
protein Rad51 (Fig 3 and Table 1) in nuclear foci, 
and for efficient homology-directed repair.  In cells 
expressing SV40 large T antigen, Rad51 foci depend 
on PML.  
In myeloid leukemias, chromosome 17 
(containing BRCA1) is frequently lost or involved 
in complex chromosomal abnormalities including 
balanced translocations involving the BRCA1 locus 
[Zhu et al (2008)] (Table1 and Fig. 3).  Some patho-
genic mechanisms in leukemias may be related to 
those in hereditary breast cancers.   
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Table 2.  Risks of leukemia and oral cavity cancers as cancers following breast, ovarian or fallopian 
tube cancer in proven or potential BRCA1/2 mutation carriers
Row number, Study population and 
reference
Mutation test status
Risk measurement for leukemias [Con-
fidence interval]
1. 6 children with biallelic BRCA2 
mutations [Wagner (2004)].
Biallelic BRCA2 mutations (com-
pound heterozygotes)
All developed leukemia at median age 2.2 
years.  4 of 6 AMLs 
2. Review of 27 biallelic BRCA2 muta-
tion patients [Alter (2003)]. 
Biallelic BRCA2 mutations (com-
pound heterozygotes)
79% cumulative probability of leukemia 
(primarily AML) by age 10 years  
3.   First breast cancer age <45 in 6958 
Connecticut women.  [Harvey & Brin-
ton, 1985]
Potential mutation carriers eligible 
for mutation testing
Acute non-lymphocytic leukemia as 2nd 
cancer O/E=2.9 at 1-4 years and 6.4 at 
5-9 years 
4.   Breast cancer patients, age 35-49 from 
26,617 primary female breast cancers 
[Teppo et al, 1985]
Potential mutation carriers eligible 
for mutation testing
Subsequent leukemia (excluding CLL) RR= 
3.21 p<.01
5.   Female breast cancer surviving >= 10 
years (selects 11,273 younger patients) 
[Ewertz & Mouridsen, 1985]
Potential mutation carriers eligible 
for mutation testing
Acute non-lymphocytic leukemia as a 2nd 
cancer RR=2.3
6.   2813 women with 2 breast or ovarian 
cancers in Thames Cancer Registry. 
[Evans et al, 2001b]  
Potential BRCA1/2 mutation carri-
ers eligible for mutation testing Myeloid leukemia RR=5.04 [1.85-11.0]
7.   82,520 Women with breast cancer age 
<=45 in 13 cancer registries. [Mellemk-
jaer et al, 2006]
Potential mutation carriers eligible 
for mutation testing
Myeloid Leukemia  SIR = 3.02 (2.32–3.85) 
Leukemia SIR = 2.16 (1.78–2.59).
8.   2,084 Women with primary fallopian 
tube cancer from 13 cancer registries 
[Riska et al, 2007]
Probable BRCA1/2 mutation car-
riers.  Non-lymphoid leukemia RR=3.7 (1.0-9.4) 
9.   2nd cancer after Breast Cancer<50. 
from 32, 799 patients in Thames Can-
cer Registry. [Evans et al, 2001a]
Potential BRCA1/2 mutation carri-
ers eligible for mutation testing Myeloid leukemias RR=2.31 [1.52-3.51]
10.   2nd cancer after male breast cancer 
[Hemminki et al, 2005] 
Men at high risk for being (BRCA2) 
mutation carriers eligible for muta-
tion testing
Myeloid leukemia RR=3.98 [1.46 – 8.67] 
1-9 yrs of follow up.  RR=3.42 [1.47-6.73] for 
all periods
11.   534 First degree relatives of BRCA1  
probands with ovarian cancer [Risch 
et al, 2006]
Tested BRCA1 heterozygotes or 
potential carriers eligible for testing
Leukemias, lymphomas, etc RR=3.7 (1.5 
to 9.5) 
12.   7/98 multiple primary cancer fami
lies with a BRCA1 mutation and 
8/98 multiple primary cancer fami
lies with a BRCA2 mutation 
[Shih et al, 2000]
Known BRCA1 and BRCA2 muta-
tion carriers
20% of leukemias in the families occurred 
in BRCA1 and BRCA2 mutation carriers.  
13.   3678 women, 50 men. 1st degree 
relatives of BRCA2 mutation car-
riers or of breast or ovarian cancer 
patients [Breast cancer linkage 
consortium, 1999] 
471 BRCA2 carriers, 390 noncar-
riers, and 2186 unknown BRCA2 
carrier status 
Leukemia RR= 1.12 [0.30–4.25]
14.   11847 individuals from 699 families 
segregating a BRCA1 mutation 
[Thompson et al, 2002]
18.9% (2245) tested BRCA1 car-
riers, 9.3% (1106) tested negative, 
71.7% (8496) untested.  
Leukemia RR = 0.88 [0.37 to 2.14] p=.83 
15.   1811 male and female family mem
bers [Van Asperen et al,  2005]
50% probability BRCA2 mutation 
from 139 BRCA2 families. Leukemia RR= 1.5 [0.5 to 3.5]
16.   728 males & females (BRCA2). 
1145 males & females (BRCA1) 
[Johannson et al, 1999]
From families with an identified 
BRCA2 or BRCA1 mutation
Acute leukemia SMR=1.54 [0.04±8.59] 
(BRCA2). 1.01 [0.03±5.62] (BRCA1)
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Studies of heterozygotes or potential heterozygotes listed in Table 2
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with breast cancer in southeast England. Brit J Cancer 84: 435-440 
Evans H., Lewis, C., Robinson, D. et al. (2001b) Cancer risks in women with 2 breast or ovarian cancers: clues to genetic cancer susceptibility. 
Int J. Cancer 94: 758-9
Ewertz, M. & Mouridsen, H.  Second cancer following cancer of the female breast in Denmark, 1943-80. Natl Cancer Inst Monogr. 1985; 
88:325-9
Harvey EB and Brinton LA. Second cancer following cancer of the breast in Connecticut, 1935–1982. Natl Cancer Inst Monogr 1985; 68, 
99–109
Hemminki K, Scélo G, Boffetta P, Mellemkjaer L, Tracey E, Andersen A, Brewster DH, Pukkala E, McBride M, Kliewer EV, Chia KS, Pompe-Kirn 
V, Martos C, Jonasson JG, Li X, Brennan P.  (2005)  Second primary malignancies in patients with male breast cancer.  Brit. J. Cancer 92 : 
1288-92. 
Johannsson O, Loman N, Moller T, Kristoffersson U, Borg A, Olsson H. Incidence of malignant tumors in relatives of BRCA1 and BRCA2 germ-
line mutation carriers (1999). Eur J Cancer 35:1248–57
Mellemkjaer L, Friis S, Olsen JH, Scélo G, Hemminki K, Tracey E, Andersen A, Brewster DH, Pukkala E, McBride ML, Kliewer EV, Tonita JM, Kee-
Seng C, Pompe-Kirn V, Martos C, Jonasson JG, Boffetta P, Brennan P.  (2006). Risk of second cancer among women with breast cancer. Int J 
Cancer 118(9):2285-92.
Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, Tang J, Li S, Zhang S, Shaw PA, Narod SA.  (2006) Population BRCA1 and BRCA2 
mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst. 98(23):1694-706.
Riska A, Pukkala E, Scélo G, Mellemkjaer L, Hemminki K, Weiderpass E, McBride ML, Pompe-Kirn V, Tracey E, Brewster DH, Kliewer EV, Tonita 
JM, Kee-Seng C, Jonasson JG, Martos C, Boffetta P, Brennan P.  (2007)  Second primary malignancies in females with primary fallopian 
tube cancer. Int J Cancer 120(9):2047-51.
Shih H, Nathanson K, Seal S, Collins N, Stratton M, Rebbeck T and Weber B. (2000).  BRCA1 and BRCA2 mutations in breast cancer families 
with multiple primary cancers. Clin Cancer Res 6, 4259-64. 
Teppo L, Pukkala E and Saxen E.  (1985)  Multiple cancer – an epidemiological exercise in Finland. J Natl Cancer Inst 75: 207–217.
Thompson D, Easton DF; Breast Cancer Linkage Consortium (2002).  Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 
94(18):1358-65 
van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, Hoogerbrugge N, Verhoef S, Vasen HF, Ausems MG, Menko FH, Gomez Garcia EB, Klijn JG, Ho-
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(HEBON). (2005)  Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet. 42(9):711-9.
Footnotes:  NR= Not reported.  Confidence intervals are given in brackets.  #RR=1.1 for mouth cancer.  * Head/neck and 
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Formaldehyde and acetaldehyde in-
crease risks for leukemias in model studies.  
Formaldehyde is now a proven cause of human 
myeloid leukemia which develops at 2 – 5.9 ppm 
formaldehyde in air.   Myeloid leukemia was a pro-
totype in formulating the cancer stem cell theory.  
Search results in model systems show a connec-
tion between formaldehyde and stem cell damage. 
As measured by increases in characteristic stem 
cell pathways,  formaldehyde activates and dam-
ages stem cells during carcinogenesis.  [Andersen 
et al. (2010)].  
Rats fed either acetaldehyde or formal-
dehyde in their drinking water have very high 
incidence of leukemias and lymphomas [Soffritti 
et al, (2002)].  BRCA / Fanconi anemia pathways 
are required to counteract teratogenic and carci-
nogenic effects of aldehydes in mice [Langevin et 
al (2011)]  Model studies involving acetaldehyde 
show oxidative DNA damage via the metabolism 
of ethanol by the ADH1B/ALDH2 pathway [Yan 
et al. (2011)].  
Relative risk data shows human mutation 
carriers have increased risks for leukemias
 Associations between BRCA1/2 mediated 
pathways and myeloid leukemia predicted from 
model studies were independently tested against 
mutation related risks for myeloid leukemia from 
epidemiologic studies.   Table 2 shows this asso-
ciation is especially strong for homozygous or bi-
allelic mutations in BRCA2 (Fanconi protein D1).  
Six children with biallelic BRCA2 mutations all 
developed leukemia at median age 2.2 years, with 
4 of 6 developing acute myeloid leukemia (AML) 
[Wagner et al. (2004)].  Biallelic BRCA2 muta-
tion patients have a 79% cumulative probability of 
leukemia (primarily AML) by age 10 years [Alter 
(2003)] (Table 2).  
Homozygous or biallelic mutations in 
BRCA1 are incompatible with human life but 
heterozygous BRCA1 mutations are well known.  
Carriers of heterozygous mutations in either 
BRCA1 or BRCA2 have increased risks for myeloid 
leukemia.  Rows 3 through 16 of Table 2 summa-
rize risks for myeloid leukemia from 14 studies of 
known/potential heterozygous BRCA1/2 mutation 
carriers or individuals eligible for mutation testing.  
Most studies reported elevated risks for leukemia 
or other hematopoietic cancers.  Risks may be even 
greater because none of the heterozygote studies 
included populations that had all tested positive for 
mutation and very ill cancer patients may have been 
lost to follow up. 
 Mutations in other pathway genes 
increase risks for leukemias: Fanconi anemia 
genes.  Fanconi anemia is an inherited cancer con-
dition caused by inactivation of one of 13 Fanconi 
anemia complementation groups.  In Fanconi ane-
mia patients, summary relative risks for AML were 
703.3 [363.7–1354.5] [Friedenson (2007)].   This 
suggests that functional Fanconi proteins are es-
sential to prevent generation of cancer stem cells 
and AML [Tischkowitz et al. (2004)].   Few stringent 
genotype–phenotype connections have emerged for 
Fanconi anemia.  Other genes and environmental 
factors may modify the phenotype [Neveling et al. 
(2009)].
Mutations in Fanconi genes contribute to 
a subset of sporadic AML [Lensch et al. (2003), 
Condie et al. (2002), Xie et al. (2000)].  In heterozy-
gous carriers, lymphocytes show increased sensitiv-
ity to mutagens, but are not blocked in G2 phase 
as in full Fanconi Anemia [Rischewski et al (200), 
Mohseni et al. (2009].   Heterozygous mutation in 
the Fanconi J gene prevents the encoded helicase 
from unwinding DNA [Wu et al. (2010]], suggesting 
one mechanism.    
ATM mutations.   ATM may prevent onco-
genic translocations by preventing excessive loading 
of recombinational repair proteins onto transloca-
tion breakpoint cluster regions (“hotspots”) [Sun et 
al. (2010), Bredemeyer et al. (2006)].  Chromosomal 
translocations involving the MLL (Multi Lineage 
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Leukemia) gene on chromosome 11q23 are very 
common in infantile and secondary leukemias.  
The ATM gene is near MLL and ATM deficiencies 
increase the frequency of 11q23 translocations.  
MLL rearrangements at the 11q23 breakpoint 
cluster region occur in approximately 15% of pa-
tients with AML and ALL and represent a WHO 
subtype [Zhang, Rowley, (2006)]. 
More than 70 MLL translocations have 
been reported in de novo and therapy related 
AML or ALL.  In contrast to most chromosome 
translocations in leukemia, a strong non-homol-
ogous end joining repair signature exists at all 
of these chromosome translocation breakpoint 
junctions [Zhang, Rowley, (2006)].  This shows 
repairs were not BRCA1/2 pathway mediated 
homologous recombination.    
ATM is an important sensor of reactive 
oxygen species.  Activated ATM fails to stimulate 
checkpoint kinases (Fig 3) in AML [Boehrer et 
al. (2009)].  Searches of epidemiologic studies 
found isolated reports of AML associated with 
ATM mutation, but malignancies in the lymphoid 
branches of hematopoetic cell development are 
more common.   
Relative risk data linking acetaldehyde/al-
cohol and leukemias.  
 Searches of human epidemiologic studies 
found associations between alcohol and myeloid 
leukemias.   Alcohol consumption during preg-
nancy caused a 56% increased risk for childhood 
AML (Latino-Martel et al (2010).  In children 
born to women who drank during the second or 
third trimester of pregnancy,  odds ratios for leu-
kemia were 10.48 [2.8 - 39.1] [Shu et al. (1996)].  
Breast cancer risks due to acetaldehyde in 
model studies.  
 Acetaldehyde causes mammary cancers 
in rodents.   In Sprague-Dawley rats, the number 
of malignant mammary tumors increased in all 
females who consumed acetaldehyde in their drink-
ing water.  Some malignant mammary tumors also 
occurred in treated males [Soffritti et al (2002)].  An 
exaggerated blood acetaldehyde response that has 
been reported after giving ethanol to pregnant rats 
begins a much larger alteration during lactation.  At 
the end of pregnancy, there is a 4-fold increase in 
acetaldehyde above nonpregnant values after an in-
tragastric dose of 3 g/kg ethanol. During gestational 
days 1 to 17, the levels did not differ.  After delivery, 
the exaggerated acetaldehyde response to ethanol 
increased, producing acetaldehyde concentrations 
15-fold greater than in nonlactating controls [Gor-
don et al (1985)].
Whether acetaldehyde exists in human 
breast milk has been controversial.  However Wako 
(1953) identified acetaldehyde in human milk based 
on paper chromatography.   Adachi et al (1991) 
identified an adduct of acetaldehyde and trypophan 
in human milk and in breast-fed infant urine.  Breast 
tissue contains alcohol and aldehyde dehydrogenas-
es and ADH is highly expressed in normal human 
mammary epithelium.   Breast tissue can convert 
ethanol to acetaldehyde and free radicals [Triano et 
al. (2003), Maciel et al. (2004)].  This evidence sup-
ports the idea that acetaldehyde occurs in breast 
milk and breast feeding mothers transfer it to 
infants.  
Acetaldehyde/alcohol and breast can-
cer risks in potential mutation carriers.  In the 
general population >100 published studies find that 
drinking alcohol increases breast cancer risk.  A me-
ta-analysis of data from 322, 647 women including 
4335 cases of breast cancer found a 50% higher risk 
associated with alcohol for women with a history of 
maternal breast cancer.  More specifically, six studies 
listed in Table 3 support an association between al-
cohol consumption and early onset breast cancers, 
including those in BRCA1/2 mutation carriers.
Three studies in Table 3 concluded that the 
ADH genotype plays a role in early onset breast 
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or get breast cancer years sooner if they consume 
alcohol.  Table 3 also cites a study of young women 
with benign breast disease, a risk factor for breast 
cancer.  Young women with a family history of 
breast cancer or benign breast disease who con-
sumed alcohol doubled their risk of benign breast 
disease [Berkley et al (2011)]. Evidence from 
cancer, presumably by increasing acetaldehyde 
accumulation.  This supports acetaldehyde in-
creasing breast cancer risk in BRCA1/2 mutation 
carriers.   Two additional results in Table 3 [Va-
chon et al (2001), Moorman et al (2011)] show 
that women who are potential or known muta-
tion carriers have higher risks for breast cancer 
Reference Patients Results
Terry et al (2006)
>1000 breast cancer patients and fast 
alcohol metabolizers based on ADH 
genotype 
Premenopausal breast cancer risk 
OR=2.9[1.2-7.1]  for 1-2 drinks per 
day
Coutelle et al 
(2004)
ADH1C genotype in 117 moderate alco-
hol consumers with breast cancer.  The 
ADH1C*1 allele was significantly more 
frequent in moderate alcohol consum-
ers with breast cancer vs. age-matched 
alcoholic controls without cancer (62% 
vs. 41.9%)
Women with the ADH1C*1,1 geno-
type had 1.8 times more risk for 
breast cancer than those with another 
genotype
Vachon et al 
(2001)
Daily drinkers who were first degree 
relatives of breast cancer probands
RR=2.45 [1.2-5.02]
Freudenheim et 
al (1999)
134 premenopausal, 181 postmenopausal  
breast cancer patients with an efficient 
form of ADH vs controls with similar 
alcohol intakes
Premenopausal breast cancer risk 
OR=3.6[1.5-8.8] 
Moorman et al. 
(2011)
Females age >=20 diagnosed with breast 
cancer and tested for BRCA1/2 muta-
tions.  283 BRCA1 and 204 BRCA2 posi-
tive cases
BRCA1/2 mutation carriers who 
consumed alcohol got breast cancer 
1.7-2.9 years younger than those who 
did not drink
Berkey et al. 
(2011)
Females age 9-15 in 1996.  In 2005-2007 
surveys, 67 of 6888 women age 18-27 
reported benign breast disease and 6741 
reported no benign breast disease
Young women whose mothers or 
aunts had breast cancer were more 
likely to have benign breast disease 
(OR=2.34), as were those with mater-
nal benign breast disease (OR=1.59). 
Adolescents with a family history of 
breast cancer who consumed 7 alco-
hol drinks/wk doubled their benign 
breast disease risk (OR=2.28) 
Table 3 Epidemiologic studies of acetaldehyde/alcohol exposure in early onset breast cancers
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
11
.6
66
8.
1 
: P
os
te
d 
5 
De
c 
20
11
-16-
breast cancer clusters on Long Island, New York 
also suggests that alcohol may increase risk in 
mutation carriers.  Women who lived in this area 
and developed breast cancer were more likely to 
use alcohol and to have risk factors associated 
with BRCA mutations.  BRCA mutation related 
risk factors included Ashkenazi Jewish heritage 
and a family history of breast cancer.   
Adding risks from BRCA1/2 pathway 
mutations to those associated with variations in 
alcohol metabolism and estrogen elevation may 
make some women at especially high cancer risks 
from alcohol use.   Acetaldehyde elevation in 
drinkers associates with high estrogen menstrual 
phases and with oral contraceptive use [Eriks-
son et al (1996), Cannizzaro et al (2010)].  The 
enzyme encoded by ADH1C may participate in 
estrogen metabolism.  In premenopausal women 
alcohol associates with higher blood estrogen 
levels although some studies found this only oc-
curred in women using oral contraceptives.  Even 
small amounts of alcohol given to healthy women 
led to an increase in estradiol of 27-38% when 
alcohol was detectable in the blood  [Coutelle et 
al (2004)]. 
Formaldehyde and breast cancer 
risks.  In contrast to evidence linking alcohol 
and acetaldehyde to breast cancer, similar links 
to formaldehyde were difficult to find.  However 
searches found  a toxicologic study in Sprague-
Dawley rats treated with formaldehyde or methyl 
alcohol, a precursor.  The number of malignant 
mammary tumors increased in females treated 
with 100 mg/L formaldehyde or methyl alcohol 
alone.  Some malignant mammary tumors were 
also found in treated males [Soffritti et al (2002)] 
Formaldehyde in the environment has 
been positively associated with breast cancer 
risk [Coyle et al. (2005)]. Greater numbers of 
DNA-protein cross-links were found in the white 
cells of breast cancer patients than in matched 
controls [Wu et al. (2002)].  Higher activity of 
ALDH1 (cytosolic) aldehyde dehydrogenase in 
BRCA1 breast stem cells and hematopoietic 
cancer stem cells suggests less ability to remove 
aldehydes and greater susceptibility to muta-
genic effects.   
BRCA1/2 mutation carriers have 
widely varying cancer risks.  There is no 
single breast or ovarian cancer risk associated 
with BRCA1/2 carrier status [Begg et al. (2008)]. 
Defective BRCA genes increase risks for can-
cers in organs other than breast and ovary but 
individual risks again differ greatly [Friedenson 
(2005)]. These results implicate an increased 
susceptibility in organs exposed to environ-
mental carcinogens and/or deficits in additional 
genes [Friedenson (2010a)].   
Discussion
 Treatment related risk factors 
for myeloid leukemia.   Fig. 3 suggests that 
inherited BRCA1/2 pathway defects predispose 
to myeloid leukemias from any cause.   Adding 
cancers related to known chronic infectious 
agents stresses the influence of enviromental 
carcinogens.
Risks also include chemotherapy and 
radiation treatment for breast cancers.  The 
lack of data separating risk factors from treat-
ment risks makes it difficult to determine risks 
associated with treatment.  Myeloid leukemias 
are diagnosed at a median age of 67 so they 
normally occur after early onset breast cancers.  
Early onset breast cancer patients treated with 
certain chemotherapy drugs are more likely to 
develop AML.  Drugs linked with these sec-
ondary (treatment related) leukemias include 
mechlorethamine, procarbazine, chlorambucil, 
melphalan, etoposide, teniposide and cyclophos-
phamide. Combining these drugs with radia-
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tion therapy further increases the risk. [Casorelli 
et al (2003)].  Infection prophylaxis with myeloid 
growth factors during chemotherapy could further 
increase risks.
Several publications in Table 2 addressed 
treatment related risks directly or provide some 
data that does.   AML occurs with virtual certainty 
in children and infants with biallelic mutations in 
BRCA2.  AML also occurs at very young ages in 
Fanconi anemia patients, before any chemotherapy 
or radiation has been given. Moreover defects in 
pathways requiring normal BRCA gene function 
are associated with other hematopoietic malig-
nancies that are not generally considered to be 
therapy related [Friedenson, 2007].
 The first chemotherapy regimen for breast 
cancer was not published until 1975 with large 
trial results appearing in 1976 [DeVita and Chu 
(2008)].  Three 1985 studies in Table 2 include 
patients diagnosed with breast cancer before 
adjuvant chemotherapy became widely used.  In 
comparison to later studies, the three pre-chemo-
therapy studies in Table 2 do not show substantial-
ly less risk for AML than the later studies.  In the 
Harvey and Brinton study,  women over 55 had no 
excess risk for any second cancer while women 
younger than 55 still had over 3 times the risk 
for myeloid leukemia.  Neither group was likely 
to receive routine chemotherapy.   Teppo et al 
(Table 2) found no difference vs age in subsequent 
new primary cancers in 1953-79 in any age group.   
Observations of approximately the same risk for 
AML before and after 1975 is not compatible with 
the fact that chemotherapy was given to a larger 
proportion of breast cancer patients during later 
periods [Table 2, Mellemkjaer, et al (2006) Evans 
et al, (2001a)]  Hemminki et al. (Table 2) found no 
trend for increasing myeloid leukemia risk with 
follow up time.   
A few more recent studies in Table 2 show 
no excess risk for myeloid leukemia, consistent 
with environmental or additional genetic varia-
tion.   Although some platinum chemotherapy did 
significantly raise risks for myeloid leukemias, these 
risks are only sightly higher than the other studies 
[(Table 2) and Riska et al (2006)].  
Radiation therapy. Therapeutic doses 
of targeted field radiation cause very little or no 
increased risk of myeloid cancers.  This is consistent 
with myeloid stem cells being more radiation resis-
tant than non-stem cells [Diehn et al. (2009)]
Despite younger ages, breast cancer patients 
with BRCAI/2 mutations present at a similar stage, 
display a normal acute reaction to radiotherapy 
and have a similar prognosis compared to sporadic 
breast cancer patients [Gaffney et al (1998)].   An 
increased risk of radiation therapy related-AML 
is largely confined to young women with stage III 
breast cancer, (spread to lymphoid tissue).  These 
patients are more likely to receive radiation in 
some combination with cytotoxic chemotherapy. In 
stage 1 disease, radiation is given alone and there is 
very little excess risk for AML [Martin et al, 2009].   
Harvey and Brinton (1985) found only minor differ-
ences in AML risks for women given radiotherapy 
vs those who were not.  
Activities of detoxification pathways 
may further stratify risks.  Genetic polymor-
phisms that affect activities of detoxification en-
zymes and behavior are potential lurking variables 
in assigning cancer risks from formaldehyde and 
acetaldehyde.  Activity of dehydrogenases, oxido-
reductases, and cytochrome P450 enzymes should 
further stratify risks among mutation carriers.   
Broader genetic testing and pharmacologic/nutri-
tional detoxification are possible.  
Most epidemiologic studies consider only 
one polymorphism but cancer risk is determined 
by variants of many enyzmes in several pathways.  
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Moreover the statistical power of these studies 
is low because some polymorphisms are scarce.  
Despite these limitations, six studies in Table 3 
show that alcohol consumption increases breast 
cancer risk in potential BRCA1/2 mutation car-
riers and three of these studies link increased 
risks to variation in alcohol detoxification genes. 
Results here imply that carcinogens and 
differing routes of exposure are major reasons 
different cells and stem cells are targeted for 
cancer.  Exposure to mutagens from alcohol 
metabolism occurs primarily in the digestive 
tract and liver but acetaldehyde, alcohol and 
detoxification enzymes also occur in the breast.  
Inherited differences in the intrinsic ability to 
metabolize alcohol or to detoxify other car-
cinogens contributes to determining the organs 
where cancer occurs.  
  There are unrelated examples of in-
herited cancer associated conditions that have 
increased susceptibility to environmental carcin-
ogens.   Common findings are increased sensitiv-
ity to cancer associated infections, to radiation, 
and to chemical carcinogens.  This shows that 
the phenomenon of increased sensitivity to 
environmental carcinogens formaldehyde and 
acetaldehyde are probably representative of a 
broad general phenomenon.  Further studies of 
relationships among genetic deficiencies, cancer 
stem cells and environmental carcinogens are 
needed.
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